Drug Trial Radar · NCT07578649
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Oct 14, 2026
Primary completion
Jun 1, 2029
Study completion Jan 30, 2031
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)
- First posted
- May 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy. Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. Our bodies have a built-in DNA "spell-checker," called the mismatch repair (MMR) system, that fixes genetic mistakes. In most endometrial cancers, this system works normally, and these cancers are called MMR-proficient (pMMR). However, pMMR tumors are harder for the immune system to recognize and attack. When endometrial cancer has spread beyond the uterus or comes back after previous treatment, it is called advanced or recurrent endometrial cancer. This study is for adults with mismatch repair-pMMR advanced or recurrent endometrial cancer. Participants must meet key criteria, including: * Women who are 18 years or older, and not pregnant at the time of joining the study * pMMR endometrial cancer only * Measurable Stage III disease, Stage IV disease (with or without measurable disease) per FIGO staging, a system doctors use to describe how far cancer has spread in the body, or recurrent (with or without measurable disease) endometrial cancer * Has not received chemotherapy except for chemotherapy given after the main surgery and more than 6 months before relapse * Be in good enough health to receive study treatment. Approximately 600 adult women will be enrolled. Each participant will be randomly assigned (like a flip of the coin) to one of two treatment groups, with about half in each group. The study is open, meaning both the doctors and participants know what treatment is being given. Participants will receive their assigned treatment through intravenous infusions (medicine is given directly into a vein). The treatment will be given in cycles. Experimental Group will receive new study medicine called PF-08634404 plus chemotherapy. It will be followed by PF 08634404 alone for up to 2 years (35 cycles). Control Group will receive an approved medicine called pembrolizumab plus chemotherapy. It will be followed by pembrolizumab alone for up to 2 years (20 cycles). The study will include regular visits for: * Participants will have regular visits to the study site for treatment, health checks, and tests. * After stopping treatment, participants will come for a final visit within a month to check their health and review any reactions. * Follow-up will continue every 12 weeks by phone or in person or by reviewing health records. This helps check health and any new treatments. * Tests will be done every 9 weeks during the first 104 weeks to see how the cancer is responding. After that, tests will be done every 12 weeks.
Conditions
- Endometrial Neoplasms
- Endometrial Cancer
Interventions
PF-08634404Biological
Solution for IV infusion
PembrolizumabBiological
Solution for IV infusion
Standard of Care ChemotherapyDrug
Solution for IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) using RECIST v1.1 as assessed by Blinded Independent Central Review (BICR)Time frame: Approximately 36 months
Locations
54 sites in 5 countries. Site status is shown where the registry gives one.
Jupiter Medical Center/ Anderson Family Cancer Institute
Jupiter, Florida · Recruiting
Orlando Health Ambulatory Care Center
Orlando, Florida · Recruiting
Orlando Health Cancer Institute
Orlando, Florida · Recruiting
Orlando Health Orlando Regional Medical Center
Orlando, Florida · Recruiting
Orlando Health Winnie Palmer Hospital for Women & Babies
Orlando, Florida · Recruiting
Minnesota Oncology Hematology, PA
Coon Rapids, Minnesota · Recruiting
Minnesota Oncology Hematology, PA
Edina, Minnesota · Recruiting
Minnesota Oncology Hematology, PA
Maple Grove, Minnesota · Recruiting
Minnesota Oncology Hematology, PA
Maplewood, Minnesota · Recruiting
Minnesota Oncology Hematology, PA
Woodbury, Minnesota · Recruiting
The Center of Hope
Reno, Nevada · Recruiting
New York Oncology Hematology
Albany, New York · Not yet recruiting
White Plains Hospital
White Plains, New York · Recruiting
Miami Valley Hospital South
Centerville, Ohio · Recruiting
Northwest Cancer Specialists, P.C.
Happy Valley, Oregon · Recruiting
Northwest Cancer Specialists, P.C.
Portland, Oregon · Recruiting
Northwest Cancer Specialists, P.C.
Tigard, Oregon · Recruiting
Sarah Cannon Research Institute- Pharmacy
Nashville, Tennessee · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Texas Oncology - West Texas
Abilene, Texas · Recruiting
Texas Oncology-West Texas
Amarillo, Texas · Recruiting
Texas Oncology - Central South
Austin, Texas · Recruiting
Texas Oncology - Central South
Austin, Texas · Recruiting
Texas Oncology - Central South
Austin, Texas · Recruiting
Texas Oncology-West Texas
El Paso, Texas · Recruiting
Texas Oncology - West Texas
El Paso, Texas · Recruiting
Texas Oncology - West Texas
El Paso, Texas · Recruiting
Texas Oncology - Central South
Harlingen, Texas · Recruiting
US Oncology Investigational Products Center (IPC)
Irving, Texas · Recruiting
Texas Oncology - Central South
McAllen, Texas · Recruiting
Texas Oncology-West Texas
Midland, Texas · Recruiting
Texas Oncology - West Texas
Odessa, Texas · Recruiting
Texas Oncology - Central South
Waco, Texas · Recruiting
Texas Oncology - Central South
Weslaco, Texas · Recruiting
Texas Oncology-West Texas
Wichita Falls, Texas · Recruiting
Virginia Oncology Associates
Chesapeake, Virginia · Recruiting
Virginia Oncology Associates
Newport News, Virginia · Recruiting
Virginia Oncology Associates
Norfolk, Virginia · Recruiting
Virginia Oncology Associates
Suffolk, Virginia · Recruiting
Virginia Oncology Associates
Williamsburg, Virginia · Recruiting
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.